Defendant Name:
Manish Singh
Defendant Type:
Individual
Initial Case Details
Legal Case Name
In the Matter of Manish Singh and Lavos, LLC
First Document Date
10-Apr-2017
Initial Filing Format
Administrative Action
File Number
3-17920
Allegation Type
Market Manipulation
Affiliations
- Former: CEO at Lion Biotechnologies, Inc. (July 2013—December 2014)
- Former: CEO at ImmunoCellular Therapeutics, Ltd. (February 2008—August 2012)
- Former: President at ImmunoCellular Therapeutics, Ltd. (February 2008—August 2012)
- Former: Controlling Shareholder at Lavos, LLC (2011—2014)
Violations Alleged
•
Section 17(b), 5(b)(1) Securities Act
Related Violations Alleged
Manish Singh is alleged to have aided and abetted Lidingo Holdings, LLC's violation of Sec 10(b) + Rule 10b-5 of the Exchange Act (willfully/knowingly).
Manish Singh is alleged to have aided and abetted Lidingo Holdings, LLC's violation of Sec 17(a) (Not specified) of the Securities Act (willfully/knowingly).
Manish Singh is alleged to have aided and abetted Lidingo Holdings, LLC's violation of Section 17(b) Securities Act (willfully/knowingly).
Resolutions
Bars:
- Bar from participating in any penny stock offering for 5 years
First Resolution Date
10-Apr-2017
Headline Total Penalty and Disgorgement
$2,901,677
Other Defendants in Action:
